● Recruiting
Phase I
Oncology
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
What is being tested: Ponatinib, a tyrosine kinase inhibitor, is being evaluated for safety, tolerability, pharmacokinetics, and efficacy in paediatric patients aged 1-18 years…
08 Jul 2026
NCT03934372